Justin Zelin
Stock Analyst at BTIG
(1.42)
# 3,413
Out of 4,944 analysts
39
Total ratings
25%
Success rate
-2.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $43 → $56 | $12.97 | +331.77% | 2 | Aug 5, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $64 → $20 | $2.85 | +601.75% | 2 | Jul 7, 2025 | |
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.47 | +142.91% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $18.83 | +123.05% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.28 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $23.62 | +162.54% | 2 | Jul 9, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.67 | +618.56% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $6.75 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $39.86 | +213.60% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $8.21 | +228.87% | 1 | Nov 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.70 | +46,958.82% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $31.87 | +185.53% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.64 | +1,464.95% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.24 | +614.29% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $9.04 | +309.29% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $36.99 | +143.31% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $6.20 | +400.00% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $49.78 | -68.86% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.79 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.81 | +452.49% | 3 | Nov 16, 2022 |
Syndax Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $43 → $56
Current: $12.97
Upside: +331.77%
Jasper Therapeutics
Jul 7, 2025
Maintains: Buy
Price Target: $64 → $20
Current: $2.85
Upside: +601.75%
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.47
Upside: +142.91%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $18.83
Upside: +123.05%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.28
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $23.62
Upside: +162.54%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.67
Upside: +618.56%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.75
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $39.86
Upside: +213.60%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $8.21
Upside: +228.87%
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.70
Upside: +46,958.82%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $31.87
Upside: +185.53%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.64
Upside: +1,464.95%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.24
Upside: +614.29%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $9.04
Upside: +309.29%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $36.99
Upside: +143.31%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $6.20
Upside: +400.00%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $49.78
Upside: -68.86%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.79
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.81
Upside: +452.49%